drugset / Trial / NCT03685344
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
NaSequentialOpen-labelTreatment
Summary
The purpose of this phase 1 study is to evaluate the safety and anti-tumor activity of Loncastuximab Tesirine (ADCT-402) and Durvalumab in participants with Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Timeline
- Start
- 2019-02-04
- Primary completion
- 2020-10-27
- Completion
- 2020-10-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Loncastuximab Tesirine | Other / unclassified | 90 ug/kg | Intravenous |
| Subject | Loncastuximab Tesirine | Other / unclassified | 120 ug/kg | Intravenous |
| Subject | Loncastuximab Tesirine | Other / unclassified | 150 ug/kg | Intravenous |